We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+20.44%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$476M
AUM Growth
-$38.3M
(-7.4%)
Cap. Flow
-$67.9M
Cap. Flow
% of AUM
-14.26%
Top 10 Holdings %
Top 10 Hldgs %
34.45%
Holding
94
New
29
Increased
20
Reduced
12
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$16.4M |
| 2 |
Quest Diagnostics
DGX
|
+$14.4M |
| 3 |
Cigna
CI
|
+$14.2M |
| 4 |
Universal Health Services
UHS
|
+$11.8M |
| 5 |
Intuitive Surgical
ISRG
|
+$10.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$16.2M |
| 2 |
CRISPR Therapeutics
CRSP
|
+$14.4M |
| 3 |
Boston Scientific
BSX
|
+$13.6M |
| 4 |
Biogen
BIIB
|
+$13.3M |
| 5 |
CVS Health
CVS
|
+$12.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Centene
CNC
$32.1B
| $8.2M | 1.72% |
100,000
-125,000
| -56% | -$10.2M |
|
27
AbbVie
ABBV
$442B
| $8.08M | 1.7% |
+50,000
| New | +$7.67M |
|
|
VTYX
28
DELISTED
Ventyx Biosciences
VTYX
| $6.89M | 1.45% |
210,000
+110,000
| +110% | +$3.26M |
|
29
Penumbra
PEN
$12.9B
| $6.67M | 1.4% |
+30,000
| New | +$5.87M |
|
30
Cardinal Health
CAH
$56.3B
| $6.46M | 1.36% |
84,000
-116,000
| -58% | -$8.81M |
|
31
Replimune Group
REPL
$1.15B
| $5.98M | 1.26% |
220,000
+20,000
| +10% | +$416K |
|
32
Aclaris Therapeutics
ACRS
$871M
| $5.83M | 1.22% |
370,000
+30,000
| +9% | +$483K |
|
33
Viking Therapeutics
VKTX
$3.94B
| $5.64M | 1.18% |
+600,000
| New | +$2.68M |
|
|
ITOS
34
DELISTED
iTeos Therapeutics
ITOS
| $5.27M | 1.11% |
270,000
+75,000
| +38% | +$1.47M |
|
35
Intellia Therapeutics
NTLA
$1.68B
| $5.23M | 1.1% |
150,000
+25,000
| +20% | +$1.19M |
|
36
Teleflex
TFX
$5.91B
| $4.99M | 1.05% |
+20,000
| New | +$4.41M |
|
37
Cooper Companies
COO
$15B
| $4.96M | 1.04% |
+60,000
| New | +$4.43M |
|
|
WBA
38
DELISTED
Walgreens Boots Alliance
WBA
| $4.67M | 0.98% |
+125,000
| New | +$4.7M |
|
|
KDNY
39
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $4.58M | 0.96% |
+175,000
| New | +$3.88M |
|
|
RVNC
40
DELISTED
Revance Therapeutics, Inc.
RVNC
| $4.43M | 0.93% |
240,000
+90,000
| +60% | +$2.06M |
|
41
Doximity
DOCS
$4.65B
| $4.4M | 0.92% |
+131,000
| New | +$4M |
|
|
NVRO
42
DELISTED
NEVRO CORP.
NVRO
| $4.32M | 0.91% |
109,000
+9,000
| +9% | +$374K |
|
|
FOLD
43
DELISTED
Amicus Therapeutics
FOLD
| $3.99M | 0.84% |
327,000
+197,000
| +152% | +$2.22M |
|
|
AKRO
44
DELISTED
Akero Therapeutics
AKRO
| $3.84M | 0.81% |
70,000
-160,000
| -70% | -$6.86M |
|
45
PTC Therapeutics
PTCT
$6.15B
| $3.82M | 0.8% |
100,000
-63,000
| -39% | -$2.62M |
|
46
argenx
ARGX
$54.1B
| $3.79M | 0.8% |
+10,000
| New | +$3.74M |
|
47
Natera
NTRA
$45.1B
| $3.49M | 0.73% |
+87,000
| New | +$3.58M |
|
48
Envista
NVST
$4.58B
| $3.37M | 0.71% |
100,000
-340,000
| -77% | -$11.6M |
|
|
RETA
49
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.23M | 0.68% |
+85,000
| New | +$2.93M |
|
50
Privia Health
PRVA
$2.81B
| $2.95M | 0.62% |
+130,000
| New | +$3.62M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q4 2022 Portfolio in Review
As of Q4 2022, Integral Health Asset Management held 94 positions worth $476M, down 7.4% from $515M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Integral Health Asset Management withdrew a net $67.9M in Q4 2022, closing 33 positions and reducing 12 holdings. Its most notable exit was Baxter International, an estimated $16.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier.
Against the trend, Integral Health Asset Management opened a new position in Moderna worth $18M.
- Integral Health Asset Management's largest Q4 2022 buy was Moderna: 100,000 shares worth $18M.
- Integral Health Asset Management added most to BioMarin Pharmaceuticals in Q4 2022, an estimated $5.91M increase.
- Integral Health Asset Management's biggest Q4 2022 reduction was Envista, cutting an estimated $11.6M.
- Integral Health Asset Management fully exited Baxter International in Q4 2022, selling an estimated $16.2M.
- Integral Health Asset Management's ten largest holdings make up 34% of its $476M portfolio in Q4 2022.
- Integral Health Asset Management opened 29 new positions and closed 33 in Q4 2022.
- Integral Health Asset Management's portfolio value fell 7.4% quarter-over-quarter to $476M.
Based on Integral Health Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.